Pulmonary hypertension (PH) is defined as a group of diseases characterised by an elevated mean pulmonary artery pressure (Ppa) ≥25 mmHg at rest. Recently, chronic myeloproliferative diseases (CMPD) associated with pulmonary hypertension were included in the group 5 category, corresponding to PH for which the aetiology is unclear and/or multifactorial. CMPD include chronic myelogenous leukaemia, chronic neutrophilic leukaemia and chronic eosinophilic leukaemia (which primarily express a myeloid phenotype and polycythaemia vera), idiopathic myelofibrosis, and essential thrombocytosis in which erythroid or megakaryocytic hyperplasia predominates. The purpose of this research: 1. Assess Prevalence of PH in patients with CMPD in Northern Israel 2. Describe the demographics and clinical course in patients with CMPD who are diagnosed with PH.
study will include the following: * sex * age * BMI * ethnicity * age diagnosed with Myeloproliferative disease * clinical manifestations of the myeloproliferative disease * JAK2 mutation * known hematological complications
Study Type
OBSERVATIONAL
Enrollment
150
Echocardiogram, demographic data, St George respiratory questioner
Pulmonology Institute, Carmel Medical Center
Haifa, Israel
RECRUITINGpulmonary hypertension
all patients with myeloproliferative diseases in the study will be evaluated by an echocardiogram. Pulmonary hypertension will be considered when the average pulmonary arterial pressure is equal or above 25 mmHg.
Time frame: 1 year
St George Respiratory Questionnaire
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.